SCHEMBL2482079

SCHEMBL2482079

NC(=O)c1cnc(Nc2ccccc2N2CCOCC2)cc1NCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK3 P52333 7/20 0.62
▸ IRAK4 Q9NWZ3 4/20 0.62
▸ TYK2 P29597 3/20 0.62
▸ JAK2 O60674 2/20 0.62
▸ JAK1 P23458 2/20 0.62
▸ STAT6 P42226 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.50
▸ PIK3CB P42338 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CSF1R P07333 1/20 0.49
▸ BTK Q06187 1/20 0.49
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ PIK3CD O00329 1/20 0.48
▸ PIK3C2B O00750 1/20 0.48
▸ MTOR P42345 1/20 0.48
▸ PIK3CG P48736 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474883 0.86 JAK3 (0.72) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2694355 0.86 JAK3 (0.63) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2523441 0.85 JAK3 (0.56) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2474482 0.84 JAK3 (0.65) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2481521 0.84 JAK3 (0.68) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2478491 0.81 JAK3 (0.69) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2696032 0.80 JAK3 (0.72) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2481423 0.80 JAK3 (0.64) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2480672 0.80 JAK3 (0.67) JAK3IRAK4TYK2JAK2JAK1
SCHEMBL2695578 0.80 JAK3 (0.67) JAK3IRAK4TYK2JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 — — US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 — — EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA JAK3 1/4885IRAK4 128/4885TYK2 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback